Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Net Cash Flow (2016 - 2025)

Lipocine (LPCN) has disclosed Net Cash Flow for 13 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 18.37% year-over-year to -$2.1 million, compared with a TTM value of $82481.0 through Sep 2025, up 125.01%, and an annual FY2024 reading of $1.4 million, down 11.65% over the prior year.
  • Net Cash Flow was -$2.1 million for Q3 2025 at Lipocine, down from $2.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $2.8 million in Q1 2022 and bottomed at -$8.6 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$1.1 million, with a median of -$941989.0 recorded in 2023.
  • The sharpest move saw Net Cash Flow tumbled 617.03% in 2021, then soared 906.88% in 2024.
  • Year by year, Net Cash Flow stood at -$1.6 million in 2021, then surged by 147.97% to $751536.0 in 2022, then dropped by 6.98% to $699052.0 in 2023, then soared by 252.33% to $2.5 million in 2024, then plummeted by 187.01% to -$2.1 million in 2025.
  • Business Quant data shows Net Cash Flow for LPCN at -$2.1 million in Q3 2025, $2.6 million in Q2 2025, and -$2.9 million in Q1 2025.